Delving into the Latest Updates on Hypericum perforatum Extract with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms

Jarsin, SJW, St. John's Wort extract

+ [4]

Target-

Mechanism-

Therapeutic Areas

Cardiovascular DiseasesUrogenital DiseasesOther Diseases

Active Indication-

Inactive Indication

Premenstrual SyndromeUterine HemorrhageVasomotor symptom

Originator Organization

Herbarium Laboratório Botânico Ltda

Active Organization-

Inactive Organization

Herbarium Laboratório Botânico Ltda

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC30H16O8

InChIKeyBTXNYTINYBABQR-UHFFFAOYSA-N

CAS Registry548-04-9

There are more and more herbal preparations that are used for the purpose of treatment and improvement of the clinical picture of vaginitis by patients themselves, but also by healthcare professionals. Plant species, St. John's wort, chamomile, calendula, yarrow, shepherd's purse and tea tree oil are well known for there anti-inflammatory, antimicrobial and wound healing activity. This paper presents the results of a clinical study in which three herbal formulations/vagitories, based on extracts of above mentioned plant species, were investigated for their effectiveness on non-specific vaginitis.
This was randomized controlled clinical study that included 210 women with diagnosed non-specific vaginitis. Patients were divided into two basic groups, women in reproductive stage and postmenopausal stage. Three subgroups, containing approximately 30 patients each, received one of three vagitorie formulations for 5 days during which the effects on subjective and objective symptoms were monitored.

Start Date21 Mar 2019

Sponsor / Collaborator

University of Sarajevo

[+1]

NCT03796377

/ CompletedPhase 1

Effects of Hypericum Perforatum (St. John's Wort) on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Humans

Single-center, open-label, sequential treatment study to investigate the influence of the combined P-glycoprotein and CYP3A4 inducer hypericum perforatum on the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy volunteers.

Start Date13 Feb 2019

Sponsor / Collaborator

Insel Gruppe AG

[+1]

100 Clinical Results associated with Hypericum perforatum Extract

Login to view more data

100 Translational Medicine associated with Hypericum perforatum Extract

Login to view more data

100 Patents (Medical) associated with Hypericum perforatum Extract

Login to view more data

234

Literatures (Medical) associated with Hypericum perforatum Extract

01 Nov 2024·Nursing

The perils of St. John's wort in cancer care

Article

Author: Boyle, Deborah A

Abstract:Approximately one-third of Americans use healthcare approaches including herbs and botanicals, such as St. John's wort (SJW), to improve overall well-being, gain control over their health, and manage the adverse reactions of conventional therapies. This article examines the use of SJW in cancer care, discussing its pharmacokinetics, toxicity, and potential interactions with cancer treatments while emphasizing the importance of patient education and collaboration between oncology nurses and pharmacists to ensure safe and effective care.

01 Aug 2024·Clinical and Translational Science

Dose‐dependent induction of CYP3A activity by St. John's wort alone and in combination with rifampin

Article

Author: Hohmann, Nicolas ; Blank, Antje ; Mikus, Gerd ; Haefeli, Walter E. ; Friedrichs, Anna S. ; Burhenne, Jürgen

AbstractThe dose dependence of the effect of enzyme inducers and the effect of the combined administration of two inducers that exert their effect via the same induction pathway (pregnane X receptor) have not been well studied. Using oral midazolam microdoses (30 μg), we have investigated CYP3A4 induction by St. John's wort (SJW) in 11 healthy volunteers using low (300 mg/day containing 7.48 mg hyperforin), therapeutic (900 mg/day), and supratherapeutic doses of SJW (1800 mg/day) for 14 days. SJW was then co‐administered with rifampin (600 mg/day) for a further 7 days to evaluate the effect of the combined administration of two inducers. In addition, intravenous midazolam microdoses (10 μg) were administered before SJW, at SJW 1800 mg/day, and during administration of the two inducers to assess the hepatic contribution to total induction (semi‐simultaneous administration). Administration of SJW increased oral midazolam clearance 1.96‐fold (300 mg/day), 3.86‐fold (900 mg/day), and 5.62‐fold (1800 mg/day), and 17.5‐fold after the addition of rifampin. Concurrently, the clearance of intravenous midazolam increased 2.05‐fold (1800 mg/day) and 2.93‐fold (SJW + rifampin). These results show that rifampin significantly enhances the induction of the highest SJW doses both hepatically and overall and suggest that these metabolic effects occur predominantly in the gut. These findings also suggest that in drug interactions involving strong and moderate enzyme inducers, the perpetrator effects of the strong inducer are decisive for the interaction.

01 May 2024·Clinical and Translational Science

St. John's wort extract with a high hyperforin content does not induce P‐glycoprotein activity at the human blood–brain barrier

Article

Author: Bamminger, Karsten ; Bauer, Martin ; Jackwerth, Matthias ; Lozano, Irene Hernández ; Mairinger, Severin ; Weber, Maria ; Schindler, Natalie ; Wölfl‐Duchek, Michael ; Jäger, Walter ; Poschner, Stefan ; Tournier, Nicolas ; Zeitlinger, Markus ; Rausch, Ivo ; Langer, Oliver ; Nics, Lukas ; El Biali, Myriam ; Hacker, Marcus

AbstractSt. John's wort (SJW) extract, a herbal medicine with antidepressant effects, is a potent inducer of intestinal and/or hepatic cytochrome P450 (CYP) enzymes and P‐glycoprotein (P‐gp), which can cause clinically relevant drug interactions. It is currently not known whether SJW can also induce P‐gp activity at the human blood–brain barrier (BBB), which may potentially lead to decreased brain exposure and efficacy of certain central nervous system (CNS)‐targeted P‐gp substrate drugs. In this study, we used a combination of positron emission tomography (PET) imaging and cocktail phenotyping to gain a comprehensive picture on the effect of SJW on central and peripheral P‐gp and CYP activities. Before and after treatment of healthy volunteers (n = 10) with SJW extract with a high hyperforin content (3–6%) for 12–19 days (1800 mg/day), the activity of P‐gp at the BBB was assessed by means of PET imaging with the P‐gp substrate [11C]metoclopramide and the activity of peripheral P‐gp and CYPs was assessed by administering a low‐dose phenotyping cocktail (caffeine, omeprazole, dextromethorphan, and midazolam or fexofenadine). SJW significantly increased peripheral P‐gp, CYP3A, and CYP2C19 activity. Conversely, no significant changes in the peripheral metabolism, brain distribution, and P‐gp‐mediated efflux of [11C]metoclopramide across the BBB were observed following the treatment with SJW extract. Our data suggest that SJW does not lead to significant P‐gp induction at the human BBB despite its ability to induce peripheral P‐gp and CYPs. Simultaneous intake of SJW with CNS‐targeted P‐gp substrate drugs is not expected to lead to P‐gp‐mediated drug interactions at the BBB.

100 Deals associated with Hypericum perforatum Extract

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Hypericum perforatum Extract	-	DB13014

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Premenstrual Syndrome	Phase 3	BR	Herbarium Laboratório Botânico Ltda	01 Mar 2012
Uterine Hemorrhage	Phase 3	BR	Herbarium Laboratório Botânico Ltda	01 Mar 2012
Vasomotor symptom	Phase 3	BR	Herbarium Laboratório Botânico Ltda	01 Mar 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00048815 (CTgov)	Not Applicable	Depressive Disorder	73	Citalopram (Citalopram)	xtuzuwwoqn(ydshqotsff) = ngnvuprgjw xggmxudbwe (tcvwrvlsce, rfuqnhrwyt - pagztpwbfm) View more	-	11 May 2018
				St. John's Wort (St. John's Wort)	xtuzuwwoqn(ydshqotsff) = ajuouqngsv xggmxudbwe (tcvwrvlsce, initmxldsx - xyxyopwziu) View more
NCT00110136 (CTgov)	Phase 2	Hot Flashes \| Breast Cancer	9	St. John's Wort	alnhsiltno(jshvbhfzre) = nhyiexkiob pibqkjbugd (jkkjredovr, qwnmccfqez - hcredbncdm) View more	-	29 Dec 2014
EASD2012	Not Applicable	-	-	St. John's Wort extract	rdhzjrwurf(wdgxtkqttz) = partially corrected the cytokine-induced unbalance between anti- and pro-apoptotic factors nofchgeffb (uvknkrpjrj ) View more	Positive	04 Oct 2012
				Hyperforin
NCT00587860 (CTgov)	Phase 2	Irritable Bowel Syndrome	70	St. John's wort (St. John's Wort)	flwqzipxox(npaldhqqkv) = phizljwydy njedwukwew (jiogqotrwj, ntrcfzkacl - tkxzmvjavv) View more	-	01 Mar 2010
				Placebo (Placebo)	flwqzipxox(npaldhqqkv) = egsrjrpabh njedwukwew (jiogqotrwj, fnoumpektq - qdbtvfjbdn) View more